Qiagen N.V. (NASDAQ:QGEN) was the recipient of a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 3,215,255 shares, a decline of 34.9% from the October 13th total of 4,938,525 shares. Based on an average daily trading volume, of 1,090,373 shares, the short-interest ratio is currently 2.9 days. Approximately 1.5% of the shares of the stock are short sold.
Institutional investors have recently added to or reduced their stakes in the business. Acrospire Investment Management LLC boosted its position in Qiagen N.V. by 11.7% in the 2nd quarter. Acrospire Investment Management LLC now owns 3,344 shares of the company’s stock valued at $112,000 after buying an additional 349 shares during the period. Oppenheimer Asset Management Inc. purchased a new stake in Qiagen N.V. in the 1st quarter valued at about $114,000. Quadrant Capital Group LLC boosted its position in Qiagen N.V. by 4.1% in the 2nd quarter. Quadrant Capital Group LLC now owns 5,742 shares of the company’s stock valued at $183,000 after buying an additional 225 shares during the period. Quantitative Systematic Strategies LLC purchased a new stake in Qiagen N.V. in the 2nd quarter valued at about $211,000. Finally, Prudential Financial Inc. purchased a new stake in Qiagen N.V. in the 1st quarter valued at about $207,000. 60.47% of the stock is owned by institutional investors.
Qiagen N.V. (QGEN) opened at $30.77 on Tuesday. The company has a market cap of $7,180.41, a PE ratio of 25.64, a P/E/G ratio of 1.93 and a beta of 1.13. Qiagen N.V. has a fifty-two week low of $27.51 and a fifty-two week high of $36.34. The company has a current ratio of 5.33, a quick ratio of 4.78 and a debt-to-equity ratio of 0.68.
Qiagen N.V. (NASDAQ:QGEN) last issued its quarterly earnings results on Monday, November 6th. The company reported $0.32 EPS for the quarter, meeting the consensus estimate of $0.32. The company had revenue of $364.00 million for the quarter, compared to the consensus estimate of $363.42 million. Qiagen N.V. had a net margin of 6.40% and a return on equity of 11.36%. The firm’s revenue was up 7.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.29 EPS. equities analysts predict that Qiagen N.V. will post 1.25 earnings per share for the current fiscal year.
A number of research firms have recently weighed in on QGEN. Deutsche Bank AG restated a “buy” rating on shares of Qiagen N.V. in a report on Monday, July 31st. Barclays PLC restated an “overweight” rating and issued a $37.00 target price (up from $33.00) on shares of Qiagen N.V. in a report on Monday, July 17th. TheStreet upgraded shares of Qiagen N.V. from a “c+” rating to a “b+” rating in a report on Tuesday, November 7th. Zacks Investment Research downgraded shares of Qiagen N.V. from a “buy” rating to a “hold” rating in a report on Monday, October 16th. Finally, Independent Research GmbH upgraded shares of Qiagen N.V. from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the stock. Qiagen N.V. currently has a consensus rating of “Hold” and an average target price of $34.06.
Qiagen N.V. Company Profile
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with MarketBeat.com's FREE daily email newsletter.